Esophageal Cancer Clinical Trial
Clinical Utility of Methylation-based Prognostic Assay for Barrett’s Esophagus
Summary
Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions when presented with different clinical and prognostic assay information.
Full Description
Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions for virtual patient cases when presented with different clinical and prognostic assay information. The data from this study will be published in a peer-review scientific journal.
Eligibility Criteria
Inclusion Criteria:
Be currently practicing board-certified gastroenterologist practicing in the United States
Have practiced (as a board-certified gastroenterologist) for greater than 2
Be English-speaking
Have ≥ 50 Barrett's esophagus patients under care annually
Have Internet access
Have no prior experience with the methylation assay test
Provide voluntary informed consent to participate in the study.
Exclusion Criteria:
Non-practicing gastroenterologists
Less than two years of gastroenterology practice
Non-English speaking
Does not have access to the internet
Does not consent to participate in study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Baltimore Maryland, 21215, United States
How clear is this clinincal trial information?